MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics
News provided by
Share this article
Share this article
J.R. Rahn to become sole CEO; Perry Dellelce to become Chair; Stephen Hurst retires as executive but remains on board; Stanley Glick retires as board member
TORONTO, Feb. 2, 2021 /PRNewswire/ MindMed (NEO: MMED,OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company, streamlined its leadership team to further develop the company s strategy of integrating its psychedelic clinical development programs with innovative digital technologies.
As part of this, Stephen Hurst will retire from his co-CEO and Executive Chair positions but will remain on the board of directors. Dr. Glick has retired from his position on the board of directors but will continue to act as a scientific advisor. The vacancy on the board of directors created by Dr. Glick s retirement will be filled by t